Literature DB >> 22809912

Bortezomib partially protects the rat diaphragm from ventilator-induced diaphragm dysfunction.

Anouk Agten1, Karen Maes, Debby Thomas, Nele Cielen, Hieronymus W H Van Hees, Richard P N Dekhuijzen, Marc Decramer, Ghislaine Gayan-Ramirez.   

Abstract

OBJECTIVE: Controlled mechanical ventilation leads to diaphragmatic contractile dysfunction and atrophy. Since proteolysis is enhanced in the diaphragm during controlled mechanical ventilation, we examined whether the administration of a proteasome inhibitor, bortezomib, would have a protective effect against ventilator-induced diaphragm dysfunction.
DESIGN: Randomized, controlled experiment. SETTINGS: Basic science animal laboratory.
INTERVENTIONS: Anesthetized rats were submitted for 24 hrs to controlled mechanical ventilation while receiving 0.05 mg/kg bortezomib or saline. Control rats were acutely anesthetized.
MEASUREMENTS AND MAIN RESULTS: After 24 hrs, diaphragm force production was significantly lower in mechanically ventilated animals receiving an injection of saline compared to control animals (-36%, p<.001). Importantly, administration of bortezomib improved the diaphragmatic force compared to mechanically ventilated animals receiving an injection of saline (+15%, p<.01), but force did not return to control levels. Compared to control animals, diaphragm cross-sectional area of the type IIx/b fibers was significantly decreased by 28% in mechanically ventilated animals receiving an injection of saline (p<.01) and by 16% in mechanically ventilated animals receiving an injection of bortezomib (p<.05). Diaphragmatic calpain activity was significantly increased in mechanically ventilated animals receiving an injection of saline (+52%, p<.05) and in mechanically ventilated animals receiving an injection of bortezomib (+36%, p<.05). Caspase-3 activity was increased after controlled mechanical ventilation with saline by 55% (p<.05), while it remained similar to control animals in mechanically ventilated animals receiving an injection of bortezomib. Diaphragm 20S proteasome activity was slightly increased in both ventilated groups, and the amount of ubiquitinated proteins was significantly and similarly enhanced in mechanically ventilated animals receiving an injection of saline and mechanically ventilated animals receiving an injection of bortezomib.
CONCLUSIONS: These data show that the administration of bortezomib partially protects the diaphragm from controlled mechanical ventilation-induced diaphragm contractile dysfunction without preventing atrophy. The fact that calpain activity was still increased after bortezomib treatment may explain the persistence of atrophy. Part of bortezomib effects might have been due to its ability to inhibit caspase-3 in this model.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22809912     DOI: 10.1097/CCM.0b013e3182553a88

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  14 in total

1.  Inhibition of the ubiquitin-proteasome pathway does not protect against ventilator-induced accelerated proteolysis or atrophy in the diaphragm.

Authors:  Ashley J Smuder; W Bradley Nelson; Matthew B Hudson; Andreas N Kavazis; Scott K Powers
Journal:  Anesthesiology       Date:  2014-07       Impact factor: 7.892

2.  Time course of diaphragm function recovery after controlled mechanical ventilation in rats.

Authors:  Debby Thomas; Karen Maes; Anouk Agten; Leo Heunks; Richard Dekhuijzen; Marc Decramer; Hieronymus Van Hees; Ghislaine Gayan-Ramirez
Journal:  J Appl Physiol (1985)       Date:  2013-07-11

Review 3.  Exercise: Teaching myocytes new tricks.

Authors:  Scott K Powers
Journal:  J Appl Physiol (1985)       Date:  2017-06-01

Review 4.  Endurance exercise protects skeletal muscle against both doxorubicin-induced and inactivity-induced muscle wasting.

Authors:  Scott K Powers; Jose A Duarte; Branden Le Nguyen; Hayden Hyatt
Journal:  Pflugers Arch       Date:  2018-11-13       Impact factor: 3.657

5.  Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis.

Authors:  S S Xing; C C Shen; M P Godard; J J Wang; Y Y Yue; S T Yang; Q Zhao; S B Zhang; T X Wang; X L Yang; P Delafontaine; Y He; Y H Song
Journal:  Biochem Biophys Res Commun       Date:  2014-02-10       Impact factor: 3.575

6.  Diaphragm muscle fiber weakness and ubiquitin-proteasome activation in critically ill patients.

Authors:  Pleuni E Hooijman; Albertus Beishuizen; Christian C Witt; Monique C de Waard; Armand R J Girbes; Angelique M E Spoelstra-de Man; Hans W M Niessen; Emmy Manders; Hieronymus W H van Hees; Charissa E van den Brom; Vera Silderhuis; Michael W Lawlor; Siegfried Labeit; Ger J M Stienen; Koen J Hartemink; Marinus A Paul; Leo M A Heunks; Coen A C Ottenheijm
Journal:  Am J Respir Crit Care Med       Date:  2015-05-15       Impact factor: 21.405

7.  The JAK-STAT pathway is critical in ventilator-induced diaphragm dysfunction.

Authors:  Huibin Tang; Ira J Smith; Sabah N A Hussain; Peter Goldberg; Myung Lee; Sista Sugiarto; Guillermo L Godinez; Baljit K Singh; Donald G Payan; Thomas A Rando; Todd M Kinsella; Joseph B Shrager
Journal:  Mol Med       Date:  2015-02-19       Impact factor: 6.354

Review 8.  Interactions of the super complexes: When mTORC1 meets the proteasome.

Authors:  Olasunkanmi A J Adegoke; Brendan E Beatty; Scot R Kimball; Simon S Wing
Journal:  Int J Biochem Cell Biol       Date:  2019-10-31       Impact factor: 5.085

Review 9.  Strategies to optimize respiratory muscle function in ICU patients.

Authors:  Willem-Jan M Schellekens; Hieronymus W H van Hees; Jonne Doorduin; Lisanne H Roesthuis; Gert Jan Scheffer; Johannes G van der Hoeven; Leo M A Heunks
Journal:  Crit Care       Date:  2016-04-19       Impact factor: 9.097

Review 10.  Dysfunction of respiratory muscles in critically ill patients on the intensive care unit.

Authors:  David Berger; Stefan Bloechlinger; Stephan von Haehling; Wolfram Doehner; Jukka Takala; Werner J Z'Graggen; Joerg C Schefold
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-03-09       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.